234 related articles for article (PubMed ID: 32415240)
1. Impact of Sub-Retinal Fluid on the Long-Term Incidence of Macular Atrophy in Neovascular Age-related Macular Degeneration under Treat & Extend Anti-Vascular Endothelial Growth Factor Inhibitors.
Siedlecki J; Fischer C; Schworm B; Kreutzer TC; Luft N; Kortuem KU; Schumann RG; Wolf A; Priglinger SG
Sci Rep; 2020 May; 10(1):8036. PubMed ID: 32415240
[TBL] [Abstract][Full Text] [Related]
2. Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor treatment.
Cho HJ; Song MY; Yoon W; Yoon J; Na SK; Lee J; Kim J; Kim JW
Sci Rep; 2022 Feb; 12(1):3167. PubMed ID: 35210516
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
Front Immunol; 2021; 12():738521. PubMed ID: 34721402
[TBL] [Abstract][Full Text] [Related]
4. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
5. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
6. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
[TBL] [Abstract][Full Text] [Related]
7. Analyses of the effects of persistent subretinal fluid on visual/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients.
Kim KT; Chae JB; Lee S; Seo EJ; Kim DY
BMC Ophthalmol; 2021 Aug; 21(1):294. PubMed ID: 34376158
[TBL] [Abstract][Full Text] [Related]
8. Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
Gune S; Abdelfattah NS; Karamat A; Balasubramanian S; Marion KM; Morgenthien E; Sadda SR
Ophthalmology; 2020 Apr; 127(4):523-532. PubMed ID: 31718842
[TBL] [Abstract][Full Text] [Related]
9. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
Guymer RH; Markey CM; McAllister IL; Gillies MC; Hunyor AP; Arnold JJ;
Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
[TBL] [Abstract][Full Text] [Related]
10. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
Munk MR; Ceklic L; Ebneter A; Huf W; Wolf S; Zinkernagel MS
Acta Ophthalmol; 2016 Dec; 94(8):e757-e764. PubMed ID: 27417506
[TBL] [Abstract][Full Text] [Related]
11. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration.
Shah VP; Shah SA; Mrejen S; Freund KB
Retina; 2014 Jul; 34(7):1281-8. PubMed ID: 24695062
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project.
Daien V; Nguyen V; Essex RW; Guymer R; Arnold JJ; Munk M; Ceklic L; Gillies MC; Barthelmes D;
Br J Ophthalmol; 2020 Aug; 104(8):1064-1069. PubMed ID: 31843790
[TBL] [Abstract][Full Text] [Related]
13. Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy.
Zarbin MA; Hill L; Maunz A; Gliem M; Stoilov I
Br J Ophthalmol; 2022 Nov; 106(11):1561-1566. PubMed ID: 34039560
[TBL] [Abstract][Full Text] [Related]
14. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
Inan S; Polat O; Karadas M; Inan UU
Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
[No Abstract] [Full Text] [Related]
15. Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration.
Zarubina AV; Gal-Or O; Huisingh CE; Owsley C; Freund KB
Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6038-6045. PubMed ID: 29196768
[TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF therapy in symptomatic peripheral exudative hemorrhagic chorioretinopathy (PEHCR) involving the macula.
Seibel I; Hager A; Duncker T; Riechardt AI; Nürnberg D; Klein JP; Rehak M; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):653-9. PubMed ID: 26148802
[TBL] [Abstract][Full Text] [Related]
17. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.
Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT
BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645
[TBL] [Abstract][Full Text] [Related]
18. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
Christenbury JG; Phasukkijwatana N; Gilani F; Freund KB; Sadda S; Sarraf D
Retina; 2018 Jul; 38(7):1276-1288. PubMed ID: 28723848
[TBL] [Abstract][Full Text] [Related]
19. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG;
Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
[TBL] [Abstract][Full Text] [Related]
20. The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world.
Llorente-González S; Hernandez M; González-Zamora J; Bilbao-Malavé V; Fernández-Robredo P; Saenz-de-Viteri M; Barrio-Barrio J; Rodríguez-Cid MJ; Donate J; Ascaso FJ; Gómez-Ramírez AM; Araiz J; Armadá F; Ruiz-Moreno Ó; Recalde S; García-Layana A;
Acta Ophthalmol; 2022 Mar; 100(2):e521-e531. PubMed ID: 34085771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
